Thus, our study aimed to assess the effect of SGLT2 inhibitor on liver steatosis measured by Magnetic resonance imaging Proton Density Fat Fraction (MRI-PDFF) in patients with type 2 diabetes and MASLD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.